Anatomy explorers have charted a new path myeloid cells use to access the brain. On 3 June in Neuron, scientists led by Lindsay Hohsfield and Kim Green, both at the University of California, Irvine, ...

The new paper reports that HZ vaccination eligibility decreased the probability of a new dementia diagnosis during the follow-up period of 7.4 years by 1.8 percentage points. According to the authors, ...

On April 15, two years after Eisai requested a marketing license for lecanemab in Europe, the European Commission has greenlit its use. The biologic’s long path included an initial rejection from the ...

Meanwhile, new findings from cell and animal models continued to paint a kaleidoscopic picture of TREM2 function. For example, microglia making the most TREM2—the ones scientists hope to energize with ...

Of the 20,000+ human genes, none has greater influence on late-onset Alzheimer’s disease than APOE. But why do certain variants of this lipid transporter protect the brain, while others endanger it? A ...

Most Alzheimerologists agree that lecanemab and donanemab are a start, but insufficient to treat this disease. At the Clinical Trials in Alzheimer’s Disease conference, held last month in Madrid, ...

Other news from AAIC? Long-term lecanemab dosing in open-label extensions now goes out to three years, and continues to support the idea that the antibody slows disease progression. On cognitive ...

The innate immune protein C1q seems to have a thing for neurons. Already implicated in synaptic pruning by microglia, now it is reported to also slow down protein production in neurons of the aging ...

The advisory committee voted 11 to 0 on both questions in favor of the approval of donanemab. The committee recognized, correctly I think, that the data supported a modestly favorable benefit to risk ...

Not so long ago, a blood test for Alzheimer’s disease seemed a pipe dream. Now, after years of study, the field is awash with sensitive assays that signal the proteopathic culprits Aβ and tau ...

The latest effort to rewrite the diagnostic criteria for Alzheimer’s disease has stirred more than a little controversy. While the proposed revisions have garnered praise from researchers for more ...

Current diagnostic options for PD include DaTscan SPECT to assess dopamine transporter activity, the Syn-One test to detect α-synuclein aggregates in a skin biopsy, or the SYNTap α-synuclein seed ...